PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 30, 2024SHILAP Revista de lepidopterología142 citationsOpen Access

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

NANasreen AlfarisSWStephanie WaldropVJVeronica Johnson

Key Points

Key points are not available for this paper at this time.

Abstract

National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Alfaris et al. (2024) studied this question.

synapsesocial.com/papers/69d6c52cfca0359822aa865chttps://doi.org/10.1016/j.eclinm.2024.102782
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials2019 · 157 citations
  2. 2Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study2021 · 58 citations
  3. 3Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review2023 · 75 citations
  4. 4Effects of glucagon-like peptide-1 receptor agonists on renal function2013 · 97 citations
  5. 5334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity2022 · 21 citations